Drug intelligence / Profile preview

DA-5213

Development stage: Phase 1
Lead developer: Dong-A ST
Modality: Small Molecules
Administration: Oral

Overview

DA-5213 is a new molecular entity under development by Dong-A ST. As of the latest available information, it is in preclinical development in South Korea for an undisclosed indication. The specific mechanism of action has not been defined or disclosed publicly. No orphan drug status has been assigned, and no clinical trial results or detailed pharmacological data are available at this time.

Other names: DA 5213DA5213DA-5213

Targets

CHRM3 (M3)

Beyond the preview

Go deeper on DA-5213.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-5213.

Explore the full profile